Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals
Piconi, Stefaniaa; Parisotto, Serenac; Rizzardini, Giulianoa; Passerini, Simonea; Meraviglia, Paolaa; Schiavini, Monicab; Niero, Foscaa; Biasin, Marac; Bonfanti, Paoloa; Ricci, Elena Delfinaa; Trabattoni, Dariac; Clerici, Marioc,d
aInfectious Diseases Unit
bEndocrinology Unit, Luigi Sacco Hospital
cUniversity of Milano
dFondazione Don Gnocchi, Milan, Italy.
Correspondence to Professor Mario Clerici, MD, Chair of Immunology, University of Milano, Department of Biomedical Sciences and Technologies, Via F.lli Cervi 93, 20090 Segrate, Milan, Italy. Tel: +39 02 5031 9679; fax: +39 02 5031 9677; e-mail: firstname.lastname@example.org
Received 12 July, 2012
Revised 24 September, 2012
Accepted 25 September, 2012
Objectives: HIV-infected patients have a greater burden of sub-clinical and clinical atherosclerotic disease compared to the general population. The primary objective of this study was to compare the relative roles of inflammation, endothelial alterations, and metabolic factors in the induction and maintenance of atherosclerosis in antiretroviral therapy (ART)-treated or ART-naive patients.
Design: Cross-sectional study; 79 HIV-infected patients (55 ART-treated and 24 naive individuals) were consecutively enrolled. In both groups, nearly 50% of the individuals had a high cardiovascular risk (Framingham value >20%).
Methods: Echo-Doppler [intima–media thickness (IMT)], inflammatory, thrombophilic, endothelial, metabolic indexes, and cholesterol efflux molecules were evaluated. Multivariate analysis adjusted for age, CD4 nadir, BMI, and Framingham's score were used to analyze the results.
Results: A complex pathogenesis drives atherogenesis in HIV infection. Thus, whereas inflammation could be responsible for this process in ART-naive individuals, metabolic factors [low-density lipoprotein (LDL), apolipoprotein B (ApoB), lipoprotein A] seem to play a more prevalent role in ART-treated patients. Notably, ABCA-1, an ATP-binding transporter cassette protein involved in cholesterol efflux, which is inhibited by Nef, is up-regulated in ART-treated individuals.
Conclusion: Atherosclerosis in HIV infection results from the interaction of multiple factors: an inflammatory and HIV-driven disease could prevail in the absence of therapy; metabolic, non-inflammatory causes may be more important in patients undergoing therapy. Approaches to atherosclerotic disease in HIV infection should consider these differences.
Atherosclerosis is a multifactorial, chronic, and progressive alteration of arterial blood vessels characterized by the accumulation of monocytes/macrophages, smooth muscle cells, and lymphocytes in large and medium-sized arteries [1,2]. The development of atherosclerotic lesions requires interactions between metabolic, endothelial, and inflammatory components [3,4] within a complex scenario where different factors, including hypertension, smoking, diet, obesity, insulin resistance, and infections, induce endothelial cell activation . Several evidences indicate that inflammation drives all phases of atherosclerosis [6,7]. Thus, inflammatory indexes, including C-reactive protein (CRP) , interleukin-6 (IL-6) , and tumor necrosis factor-α (TNF-α) , are consistently elevated in coronary atherosclerosis and are possible risk indexes for cardiovascular acute events.
Recent studies have demonstrated a link between infectious diseases and cardiovascular pathology; this is explained by the fact that Toll-like receptors (TLRs), which are molecules that recognize motifs expressed by pathogens, are involved in the pathogenesis of atherosclerosis (reviewed in ). In particular, the expression of TLR2 and TLR4 is augmented in human atherosclerosis plaques , and this was linked to the infiltration of inflammatory cells in the arterial wall, as well as with the progression of atherosclerotic disease . Amongst the infectious agents correlated with cardiovascular disease (CVD), HIV plays an important role. Thus, HIV infection is correlated with alterations of plasma lipoprotein metabolism , and an increased risk of CVD and myocardial infarction (MI) is observed in HIV-infected individuals (reviewed in ). HIV may directly impair high-density lipoprotein (HDL) metabolism by enhancing the transfer of HDL to apolipoprotein B (ApoB), an atherogenic protein , and/or by reducing the expression of the ATP-binding protein (ABCA-1) transporter in macrophages , favoring foam cell transformation. Notably, HIV infection could also induce the development of atherosclerosis and contribute to increased CVD risk by a direct inflammatory effect. This possibility is suggested by the observation that augmented amounts of IL-6, TNF-α, adhesion molecules, lipopolysaccharide (LPS), and CRP are seen in HIV-infected patients [15,16]. Therapy of HIV disease does not seem to reduce the risk of either CVD or acute cardiovascular events, and is associated with a high incidence of vascular episodes among younger patients .
A possible relationship between antiretroviral therapy (ART) and CVD was reported by some but not all authors [17–20]. Cumulative exposure to protease inhibitors [17–20] and nuclear reverse transcriptase inhibitors (NRTIs)  was associated with CVD. This might be due to the ability of these molecules to induce metabolic impairments and mitochondrial dysfunctions [22,23]. Thus, both HIV per se and ART seem to contribute to atherogenesis during HIV infection; no data are nevertheless available comparing the relative roles of inflammatory, endothelial, and metabolic risk factors for atherosclerosis in ART-treated or in ART-naive patients. In the attempt to clarify this issue we analyzed these factors, as well as intracellular cholesterol transport, in a cross-sectional study performed in HIV-infected patients who were or were not undergoing therapy.
Seventy-nine HIV-infected male patients were longitudinally enrolled in a cross-sectional study and subdivided in two groups (ART-treated, n = 55; naive n = 24). Nearly 50% of patients in both groups were selected to have a Framingham risk score (FRS) above 20%, allowing the definition of different subpopulations as follows: high-risk ART-treated (n = 24); low-risk ART-treated (n = 31); high-risk naive (n = 12); low-risk naive (n = 12). Patients receiving statins were excluded from the study. Interviews aimed to collect the family history with a strong emphasis on CVDs, concomitant illnesses, substance abuse, smoking, diet, and alcohol consumption. Smokers were defined as individuals smoking at least 10 cigarettes/day during the previous 6 months. Biochemical and immuno-virologic parameters were collected for all patients. A complete physical examination was also performed in all individuals. Written informed consent was obtained and the study was conducted according to ‘Good Clinical Practice’ guidelines and the Declaration of Helsinki.
Measurement of carotid intima–media thickness and plaque classification
Measurements were performed according to the guidelines of the Mannheim Intima Media Thickness (IMT) Consensus using an ATL HDI-5000 ultrasound scanner (Philips, Monza, Italy) with a 7-MHz linear transducer. Longitudinal electrocardiography (ECG)-triggered images of the right and left common carotid arteries (CCAs) were obtained proximally at 1 and 2-cm points, with the patient in supine position, the head straight, and the neck extended. The same operator performed all the analyses and was blinded to the status (absence/presence of ART) of the patient. Measurements were performed on the posterior (far) vessel wall, and images were frozen on the isoelectric line to minimize variability during the cardiac cycle. For each patient, the mean cIMT (left + right/2) was measured to evaluate the wall thickness of the distal common carotid artery. Atherosclerotic plaques were classified according to the Modified American Heart Association Consensus Classification based on morphologic descriptions.
Blood sample collection and peripheral blood mononuclear cell separation
Blood was collected by venipuncture in EDTA-containing Vacutainer tubes (ethylenediaminetetraacetic acid) (Becton Dickinson, Rutherford, New Jersey, USA). Plasma was stored and peripheral blood mononuclear cells (PBMCs) were separated on lymphocyte separation medium (Cedarlane Laboratories Limited, Hornby, Ontario, Canada).
Stimulation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells were incubated for 18 h in the presence/absence of a pool of gag + env peptides (HIV) or cytomegalovirus protein (CMV) (Microbics Biosystems, Inc., Toronto, Ontario, Canada). 10 μg/ml of Brefeldin A (Sigma–Aldrich, St. Louis, Missouri, USA) was added to cell cultures during the last 6 h for cytokine analyses.
Cell subsets were evaluated using 50 μl of EDTA-treated peripheral blood incubated for 10 min at room temperature (RT) with flourochrome-labeled mAbs [anti-CD62L, anti-CD11a, anti-HLA-DR, anti-CD4, anti-CD14 PECY5 (Beckman Coulter, Fullerton, California, USA), anti-CD36 FITC, anti-CD44 PE (Serotec, Space Import Export srl, Milan, Italy), anti-TLR2 FITC, anti-CD49d, anti-TLR4 PE (eBioscience Inc., San Diego, California, USA)]. Erythrocytes were then lyzed and cells were fixed using the Immuno-Prep EPICS Kit and Q-prep Work Station (Coulter Electronics, Miami Lakes, Florida, USA). Cytometry was performed on 200 000 events using an EPIC XL flow cytometer (Beckman-Coulter). Data were analyzed by first gating on the lymphocyte population as defined by forward and side light scatters. From this population a single-color CD4, CD8, or CD14 histogram was made, and T cells or monocytes were selected and inserted into a two-dimensional dot plot.
Plasma tumor necrosis factor-α, monocyte chemoattractant protein-1, IL-6, soluble intercellular adhesion molecule 1, and soluble vascular cell adhesion molecule 1
These molecules were analyzed using commercial ELISA kits (R&D Systems, Minneapolis, Minnesota, USA; Bender MedSystems, Vienna, Austria) following the manufacturer's instructions. Plasma concentration of each protein was calculated in relation to standard curve.
RNA extraction and reverse transcription
RNA was extracted from PBMCs using the acid guanidium thiocyanate–phenol–chloroform method, dissolved in RNase-free water, and purified from genomic DNA with RNase-free DNase (RQ1 DNase, Promega, Madison, Wisconsin, USA). One microgram of RNA was reverse-transcribed into first-strand cDNA in a 20-μl final volume containing 1 μmol/l random hexanucleotide primers, 1 μmol/l oligo dT, and 200 U Moloney murine leukemia virus reverse transcriptase (Clontech, Palo Alto, California, USA).
Lipoprotein signaling and cholesterol metabolism
PCR arrays that included a set of optimized real-time PCR primers in 96-well plates were utilized (SA Biosciences Corporation, Frederick, Maryland, USA); a SYBR Green PCR mix (Finnzymes, Espoo, Finland) was used following the procedures suggested by the manufacturer. Controls for genomic DNA contamination, RNA quality, and general PCR performance were included in each array.
Student's t test was performed to assess differences between means. When data were not distributed normally, Mann–Whitney U test was used. Categorical variables were analyzed using chi-square or Fisher's exact tests as appropriate. A multivariate analysis of variance that included in the regression equation all variables was performed to verify univariate relationships with ART treatment status (BMI, CD4 nadir, and Framingham risk score >20). The general linear model was also used for non-normally distributed variables, after rank transformation. A P value less than 0.05 was considered statistically significant. All statistical analyses were performed with the SAS/STAT, version 9.1 software (SAS Institute, Inc., Cary, North Carolina, USA).
Clinical and demographic characteristics of the patients are shown in Table 1; P values are from univariate analysis. Immunological and biochemical data were analyzed using FRS, BMI, and nadir CD4 as covariates in the multivariate model. All the results shown in this study derive from the multivariate analysis. A word of caution stems from the limited number of patients in each group: some differences (e.g. CVD history) might have reached statistical significance if more individuals would have been analyzed.
Carotid intima media thickness and atherosclerotic plaques
Echo Doppler analyses of the carotid IMT showed that IMT was consistently higher in ART-treated compared to ART-naive HIV-infected individuals (P = 0.006) (Fig. 1a). These differences could be detected in multiple sites along the carotidal axis. Additional analyses showed that carotid IMT was higher in ART-treated patients with a high cardiovascular risk score (CVS) compared to those with a low CVS and to low and high CVS-naive patients (Fig. 1b). Fibro-calcific plaques were detected in three ART-treated and in two ART-naive high-risk HIV-infected individuals.
Thrombotic and metabolic markers of cardiovascular risk
Thrombotic and metabolic parameters are reliable indexes of atherosclerotic plaques progression and were evaluated in all individuals (Table 2). Thrombotic indexes, including fibrinogen (P = 0.039) and D-dimer (P = 0.019), were lower, whereas total cholesterol (P = 0.015), low-density lipoprotein (LDL)-cholesterol (P = 0.016), ApoB (P = 0.01), lipoprotein A (P = 0.024), and homocysteine (P = 0.039) were higher in ART-treated patients (Table 2). These results suggest that CVD-associated thrombotic and metabolic parameters are differently modulated by ART: therapy diminishes thrombogenesis probably by reducing viremia, whereas it increases metabolic factors linked with the atherosclerotic plaque pathogenesis.
Analysis of these parameters in patients divided according to high/low CVS showed different trends in ART-treated and ART-naive individuals. To summarize: total cholesterol, homocysteine, and ApoB levels were higher in ART-treated patients regardless of CVS; and D-dimer was higher in patients with high CVS irrespective of treatment (Table 2). Thus, ART is associated with alterations in CVD-relevant metabolic parameters independently of CVS; CVS, on the contrary, is linked to changes in trombophilic markers.
Inflammatory parameters and pro-inflammatory cytokines
High-sensitivity CRP (hsCRP), IL-6, and TNF-α plasma concentrations were significantly lower in ART-treated individuals (Fig. 2a and Table 2) independently of the CVS (Fig. 2b and Table 2). Notably, the observation that concentration of hsCRP was higher in ART-naive individuals regardless of the CVS supports a crucial role of HIV per se in feeding inflammation.
Additional results showed that IFN-γ production by HIV antigens-stimulated CD4+ T cells was reduced (P = 0.044) in ART-treated patients, whereas a trend that did not reach significance was observed for TNF-α. Finally, IL-6- and IL-12 production by HIV-stimulated CD14+ cells was significantly reduced as well in ART-treated individuals (Fig. 2c). No differences were noticed upon stratification of patients on the basis of CVS. These data confirm that ART is efficacious in reducing the synthesis of pro-inflammatory cytokines.
Soluble adhesion molecules
Soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1) plasma levels were significantly lower in ART-treated patients (Fig. 3a); the concentration of these molecules was higher in both high and low CVS risk, ART-naive groups compared to their ART-treated counterparts (Fig. 3b).
Adhesion molecule on CD4+ T cells
Adhesion molecules expressing CD4+ T cells were significantly higher in ART-treated patients (Fig. 3c) irrespective of the CVS.
TLR4 expression on monocytes
TLR4 are molecules expressed on a multitude of cells that initiate innate immune responses by recognizing common motifs expressed by bacterial pathogens; TLRs were suggested to play a crucial role in the pathogenesis of atherosclerosis. The percentage of TLR4-expressing CD14+ monocytes was significantly lower in ART-treated individuals (data not shown) (P < 0.001) regardless of the CVS. This indicates a positive effect of therapy in decreasing LPS-driven TLR-dependent inflammation, as reported by other authors.
Lipoprotein signaling and cholesterol metabolism mRNA expression in peripheral blood mononuclear cells
HIV induces foam cell transformation in vitro as a consequence of the inhibitory effect of the viral protein Nef on ABCA-1, an ATP-binding transporter cassette protein involved in cholesterol efflux and in HDL production. Data obtained in a real-time PCR array screening for the expression of 84 genes directly involved in cholesterol metabolism showed that ABCA-1 was the only gene whose expression was significantly up-regulated in ART-treated patients. Notably, the expression of 18 other genes (AKR1D1, ANGPTL3, APOB, APOL5, COLEC12, CYP11A1, CYP39A1, CYP7A1, CYP7B1, HMGCS2, IL4, LEP, LRP1B, NPC1L1, NR1H4, PRKAA2, STAB2, VLDLR) was reduced in the same patients (data not shown).
Significant positive correlations between IL-6 and sICAM-1 and IMT were observed in ART-naive patients (IL-6: P = 0.043, sICAM-1: P = 0.006), whereas a positive correlation was detected between ApoB and IMT in ART-treated individuals (P < 0.05 in both cases). These results suggest a prevalent inflammatory pathogenesis of atherosclerosis in ART-naive, HIV-infected patients, whereas metabolic factors could be dominant in ART-treated individuals.
Results herein indicate that HIV per se and ART play crucial roles in the pathogenesis of atherosclerotic disease in HIV infection. Several factors, including immunosuppression, inflammation, the intrinsic ability of HIV to induce foam cell transformation, cumulative exposure to antiretroviral drugs, and mitochondrial and metabolic dysfunctions [12–16,22,23] were hypothesized to be involved in HIV disease-associated atherosclerosis. The relative role of these factors in the two distinct settings of patients with or without therapy has nevertheless not been assessed. Our results suggest that different atherogenic processes overlap in HIV infection. Thus, even if longitudinal data will be needed to support this hypothesis, whereas inflammation and active HIV replication could drive atherosclerosis in ART-naive individuals, metabolic alterations might be prevalent in ART-treated patients.
Modifications of the thickness of the intima–media of arterial vessels are the result of the initial damage of such vessels, allowing the penetration of inflammatory cells within the arterial walls; the progressive intima–media thickening is associated with an increased likelihood of CVD, and acute cardiovascular events. Carotid IMT was significantly worse in ART-treated compared to naive patients; this difference was more evident when patients were subdivided on the basis of cardiovascular risk, as the highest values were observed in ART-treated patients. Inflammation, the suggested main culprit for intima–media alterations, is mostly driven by viral replication in HIV disease. Our data indicate that an inflammatory condition is present in HIV disease regardless of cardiovascular risk factors, suggesting a central role for HIV in driving the inflammation involved in atherosclerosis. Plasma concentrations of hsCRP, IL-6, TNF-α, D-dimer, fibrinogen, sICAM, and sVCAM, as well as indexes of endothelial activation, were higher in ART-naive individuals, confirming earlier results [12–16,22,23]. Therapy was associated with a reduced HIV viremia and a down-regulation of inflammation, of the prothrombotic state, and of endothelial parameters, suggesting the existence of a link between these pathways and HIV replication. It is nevertheless important to underline that it has been convincingly shown that a residual inflammatory condition persists in patients with an optimal response to therapy, and can even be observed in elite controllers [24–27].
Antiretroviral therapy-associated suppression of viral replication was associated with the reduction of all inflammatory indexes. In particular, the generation of pro-inflammatory cytokines by HIV-stimulated CD4+ T cells was reduced in ART-treated patients; of note, the levels of TNF-α were clearly related to the naive status, and not to the CVS. Cytokine-producing lymphocytes are present in the atherosclerotic plaques of HIV-infected individuals ; a down-modulation of inflammatory atherosclerotic process would also be expected as a consequence of the lower expression of TLR4 seen in ART-treated individuals, as this receptor plays an important role in the progression of disease .
It is important to underline that not all atherosclerosis-associated parameters were better in HIV-infected individuals undergoing ART; thus, ApoB, lipoprotein A, and LDL levels were significantly higher in treated compared to naive patients. These results indicate that metabolic factors might be important in driving the pathogenesis of atherosclerosis in HIV-infected individuals who undergo ART. Plasma HDL concentration, an index of cholesterol efflux and cholesterol reverse transport, was higher during ART as well, suggesting a possible beneficial effect of therapy on foam cell transformation. Recent results showed that the activity of ABCA-1, a key protein in the modulation of cholesterol efflux and HDL synthesis, is inhibited by the viral protein nef. Data herein show that ABCA-1 and HDL are up-regulated in ART-treated patients. ART, reducing viral replication, could diminish nef-mediated ABCA-1 inhibition; the net effect would be an improvement in cholesterol transport that, together with ART-associated reduction of inflammatory parameters, could quench atherosclerosis .
Results showing that alterations in metabolic parameters and homocysteine levels are more severe in ART-treated patients could allow the speculation that atherosclerotic progression seen during therapy is a metabolic rather than an inflammation-driven process. Homocysteine concentration, in particular, was significantly higher in ART-treated patients; this observation may be secondary to the calcification of endothelial tissue shown to be a part of the atherosclerotic process of HIV infection . Thus, older and more vulnerable atherosclerotic plaques that undergo calcification are present in ART-treated patients. Notably, adhesion of lymphocytes expressing particular proteins including CD11a, CD44, and CD49d favors the infiltration of these cells in the plaques, leading to potentially disastrous plaque ruptures in response to an occasional inflammatory insult. Adhesion molecule-expressing CD4+ T lymphocytes were higher in ART-treated patients, indicating an increased risk for atherosclerosis complications in these individuals. These observations could justify the increased risk of CVD seen in ART-treated patients.
In conclusion, virus replication has a strong impact on inflammation, thrombophilic molecules, and foam cell transformation. ART suppresses viral replication and could reduce these atherogenic factors, but lipogenic alterations might worsen once therapy is initiated, resulting in the maintenance of the atherosclerotic process. Our study has some important limitations: in particular, due to the exploratory nature of the analysis, we did not apply any adjustment for multiple comparisons. A word of caution also stems from the cross-longitudinal design of the study: our initial findings suggest a hypothesis that will need to be tested on a larger, prospective cohort, as only longitudinal analyses will shed light on this issue. Data herein reinforce the importance of tailoring antiviral treatment in HIV disease, using antiretroviral drugs having the lowest lipogenic effect.
Author contributions: S. Piconi, D.T. and M.C. conceived the initial concept for the study, analyzed results, and wrote the paper.
S. Parisotto, M.B. and M.S. performed immunological and endocrinological analyses.
S. Piconi, G.R., S. Passerini, P.M., F.N. and P.B. enrolled the patients and collected biological samples.
E.D.R. performed statistical analyses.
First draft of the manuscript with critical review by all authors. All authors participated in the development of the study protocol and analysis plan, reviewed the study data/analysis reports, and approved the final manuscript.
Supported by Istituto Superiore di Sanità ‘Programma Nazionale di Ricerca sull’AIDS’ and Ricerca Finalizzata and Ricerca Corrente (Italian Ministry of Health).
Conflicts of interest
There are no conflicts of interest.
1. Galkina E, Ley K. Immune and inflammatory mechanism of atherosclerosis. Ann Rev Immunol 2009; 27:165–197.
2. Packard RRS, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54:24–38.
3. Cybulsky MI, Ityama K, Li H, Zhu S, Chen M, Ityama M. A major role for VCAM-1 but not ICAM-1 in early atherosclerosis. J Clin Invest 2001; 107:1255–1262.
4. Kuchibhotla S, Vanegas D, Kennedy DJ, Guy E, Nimako G, Morton RE. Absence of CD36 protects against atherosclerosis in Apo E knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovosc Res 2008; 78:185–196.
5. Choussat R, Montalescot G, Collet GP, Jardel C, Ankri A, Fillet A, et al. Effect of prior exposure to Chlamidya pneumoniae, Helicobacter pylori or cytomegalovirus on the degree of inflammation and one year prognosis of patients with unstable angina pectoris on non-Q-wave acute myocardial infarction. Am J Cardiol 2000; 86:379–384.
6. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868–874.
7. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavassiliou VG. Inflammation and atherosclerosis. Eur J Vasc Endovasc Surg 2006; 31:386–393.
8. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116 (Suppl 6A):9S–16S.
9. Mazzone A, De Servi S, Vezzoli M, Fossati G, Mazzucchelli I, Gritti D, et al. Plasma levels of interleukin 2, 6, 10 and phenotypic characterization of circulating T lymphocytes in ischemic heart disease. Atherosclerosis 1999; 145:369–374.
10. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990; 65:297–302.
11. Erridge C. The role of Toll-like receptors in atherosclerosis J. Innate Immunol 2009; 1:240–349.
12. Rose H, Hoy J, Wolley I, Tchoua U, Bukrinsky M, Dart A, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008; 199:79–86.
13. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48–62.
14. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4:e365.
15. Oliviero U, Bonadies G, Apuzzi V, Foggia M, Bosso G, Nappa S, et al. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 2009; 204:586–589.
16. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603–1608.
17. Friis-Møller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993–2003.
18. Study Group DAD, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723–1735.
19. Currier JS, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, Tebas P, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007; 21:1137–1145.
20. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747–1748.
21. The SMART/INSIGHT and the D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17–F24.
22. Shankar SS, Dubé MP, Gorsky JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005; 150:933e1–933e7.
23. Study Group DAD, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside-reverse transcriptase inhibitors and risk of myocardial infarction in HIV infected patients enrolled in the DAD study: a multicohort collaboration. Lancet 2008; 371:1417–1426.
24. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205:S375–S382.
25. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126–133.
26. Piconi S, Parisotto S, Rizzardini G, Terzi R, Argenteri B, Capetti A, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, ART-treated, immunological non responders. Blood 2011; 118:3263–3272.
27. Burdo Th, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy. J Infect Dis 2011; 204:154–163.
28. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145:33–43.
29. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127–135.
30. Coria-Ramirez E, Cisneros LN, Treviño-Perez S, Ibarra-Gonzalez I, Casillas-Rodriguez J, Majluf-Cruz A. Effect of highly active antiretroviral therapy on homocysteine plasma concentrations in HIV-1-infected patients. J Acquir Immune Defic Syndr 2010; 54:477–481.
ABCA-1; ART; atherosclerosis; HIV; immunology
© 2013 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.